Publication: The Association Of Cyp3a4, Cyp3a5 And Mthfr Genes Polymorphism On The Efficacy And Safety Of Atorvastatin Among Egyptian Population
Loading...
Date
2025-03
Authors
Maslub, Mohammed Gamal Mohammed
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Dyslipidemia raises cardiovascular diseases (cvds) risk in egyptians. Tailoring atorvastatin treatment based on genotype can enhance efficacy and reduce adverse effects, contributing to the egyptian genome project’s efforts to improve health outcomes. Previous studies have not provided conclusive evidence regarding the association between response to atorvastatin and cyp3a4 and cyp3a5 genetic polymorphisms. Further research is necessary to confirm the mthfr gene variation as a predictive biomarker for responsiveness to atorvastatin. The effects of genetic polymorphisms on atorvastatin therapy were not previously studied among the egyptians. This research aimed to investigate the effects of cyp3a4*1b (rs2740574 c/t), cyp3a4*22 (rs35599367 g/a), cyp3a5*3 (rs776746 t/c), and mthfr (rs1801133 g/a) polymorphisms on atorvastatin treatment in egyptians. In this prospective cohort study, 100 subjects were genotyped for these alleles. All participants were screened for serum lipid profiles, liver enzymes, total bilirubin (tb), and creatine kinase (ck) before and after a four-week therapy with 40 mg of atorvastatin.
Description
Keywords
Pharmacogenetics